Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: August 18, 2017
Reporting Period: Event date August 18, 2017; Report signed August 23, 2017
Business Overview: The Company is an emerging growth company focused on the development and commercialization of Nell-1, a recombinant human protein growth factor essential for normal bone development.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Entry into Material Definitive Agreement (Item 1.01):
- Agreement: Amended and Restated Exclusive License Agreement with The Regents of the University of California.
- Effective Date: August 18, 2017.
- Scope Change: The agreement amends and restates the original 2006 license. While retaining exclusive rights for spinal fusions, the Company added osteoporosis and trauma as new fields of use for the Licensed Product (Nell-1).
Guidance, Outlook, and Risks
Management Commentary: The Company continues to be responsible for the development and commercialization of Nell-1 under the expanded terms.
Other Events (Item 8.01): A press release regarding this agreement was issued on August 23, 2017.
Risks and Contingencies: The filing states that the description of the agreement is not complete and is qualified by reference to the full text of the agreement filed as an exhibit. No specific financial risks or contingencies are detailed in the summary text.
Investor Verification Checklist
- Review the full text of the Amended and Restated Exclusive License Agreement (Exhibit 10.1) to understand specific royalty obligations, milestone payments, and termination clauses.
- Verify the commercial strategy and timeline for the newly added fields of use: osteoporosis and trauma.
- Confirm the status of the Company's cash runway and funding requirements, as this filing does not disclose liquidity positions.
- Check the August 23, 2017 press release (Exhibit 99.1) for additional management commentary on the strategic impact of the expanded license.